2. UroToday Home
  3. Video Lectures

Non-Muscle Invasive Bladder Cancer Videos

36-Month Efficacy of Nadofaragene in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer - Yair Lotan
October 31, 2024
Details
BRAVO Trial Highlights Improved Detection Reduces Bladder Cancer Recurrence - Ali Nasrallah
October 31, 2024
Details
JCOG1019 Trial Examines Watchful Waiting vs BCG for High-Grade T1 Bladder Cancer - Hiroshi Kitamura
October 9, 2024
Details
Bladder Cancer Research Explores Fecal Transplants and Nutritional Strategies - Laura Bukavina
October 5, 2024
Details
SunRISe-1 Trial Advances Bladder Cancer Treatment with TAR-200 - Michiel Van der Heijden
September 27, 2024
Details
Bladder Cancer Breakthroughs in SunRISe-1, AMBASSADOR, and VOLGA Trials - Maria De Santis
September 21, 2024
Details
Harnessing Artificial Intelligence in Bladder Cancer: Digital Tools for Enhanced Diagnosis and Treatment - David McConkey
September 4, 2024
Details
Patient Perspectives on Bladder Cancer: Balancing Treatment Options and Shared Decision-Making - Roger Li
September 4, 2024
Details
Advancing Radiopharmaceuticals: Targeting Strategies and Isotope Selection in Cancer Therapy - John Babich
August 9, 2024
Details
Refined Model Improves Bladder Cancer Risk Stratification - Francesco Soria
August 8, 2024
Details
Novel Therapies for Non-Muscle Invasive Bladder Cancer: Expert Review - Felix Guerrero-Ramos
July 29, 2024
Details
ctDNA in Non-Muscle Invasive Bladder Cancer: Screening & Prognosis - Saum Ghodoussipour
July 22, 2024
Details
Early Bladder Recurrence Common in UTUC Patients Post-Nephroureterectomy Despite BCG Treatment - Paul Crispen
July 19, 2024
Details
Novel Delivery Systems and Pharmacotherapeutic Approaches for the Treatment of Non-muscle-invasive Bladder Cancer - Beyond the Abstract
July 16, 2024
Details
Novel CD40 Antibody Treatment for BCG-Unresponsive Bladder Cancer - Bernard Bochner
June 27, 2024
Details
Orion Study Evaluates Paclitaxel Conjugate for BCG-Unresponsive Cancer - Sunil Patel
June 24, 2024
Details
MoonRISe-1: Evaluating TAR-210 for Intermediate-Risk Non-Muscle-Invasive Bladder Cancer - Roger Li
June 19, 2024
Details
SunRISe-5 Trial: Evaluating TAR-200 for Recurrent High-Risk Non-Muscle Invasive Bladder Cancer - Sima Porten
June 18, 2024
Details
Adequate BCG Therapy for Very High-Risk Non-Muscle-Invasive Bladder Cancer: A Multicenter Analysis - José Daniel Subiela Henriquez
June 17, 2024
Details
Bridging the Gap in Microhematuria Evaluation: A Discussion on the STRATA Trial - Yair Lotan
June 14, 2024
Details
CORE-001 Study Demonstrates Promising Results for Bladder Cancer with Cretostimogene Grenadenorepvec and Pembrolizumab - Trinity Bivalacqua & Roger Li
June 6, 2024
Details
Apalutamide for Preventing Bladder Cancer Recurrence: A Proof-of-Principle Trial - Edward Messing
June 5, 2024
Details
Innovative Trials Highlight Progress in Treating Urothelial Carcinoma at AUA 2024 - Karim Chamie
May 24, 2024
Details
KEYNOTE-676 Cohort A: Pembrolizumab + BCG for Previously BCG-Treated NMIBC - Neal Shore
May 23, 2024
Details
AUA 2024 Urothelial Carcinoma Highlights - Woodson Smelser
May 23, 2024
Details
Immunotherapy Advancements in Bladder Cancer: Clinical Trials, Early Intervention, and Toxicity Management - Matt Galsky & Neal Shore
May 21, 2024
Details
SSANTROP Trial: Evaluating Sacituzumab Govitecan and Sasanlimab for BCG-Unresponsive Bladder Cancer - Oscar Rodriguez-Faba
May 20, 2024
Details
Managing Variant Histology in High-Risk Non-Muscle Invasive Bladder Cancer - Michael Cookson & Paolo Gontero
May 17, 2024
Details
QUILT-2.005: Comparing BCG + IL-15 Superagonist N-803 vs BCG Alone in BCG-Naïve NMIBC - Bobby Reddy
May 17, 2024
Details
Addressing BCG Supply Shortages, Workflow, and Enhancing Bladder Cancer Treatment through Strategic Partnerships - Patrick Soon-Shiong
May 16, 2024
Details
Novel Bladder Cancer Treatment: Mechanisms, Clinical Findings, and Implications - Patrick Soon-Shiong
May 16, 2024
Details
The Triangle Offense: Harnessing NK Cells, T-Cells, and Memory Cells in Bladder Cancer - Patrick Soon-Shiong
May 16, 2024
Details
AI-Based Assessment Tool for Predicting BCG Response in Bladder Cancer Patients - Yair Lotan
May 14, 2024
Details
Leveraging AI Biomarkers to Navigate the Evolving Landscape of Bladder Cancer Treatment - Stephen Williams
May 15, 2024
Details
Navigating the Expanding Landscape of BCG-Unresponsive NMIBC Treatment Options - Mark Tyson
May 10, 2024
Details
Integrating Nadofaragene Firadenovec into Clinical Practice for Non-Muscle Invasive Bladder Cancer Treatment - Ashish Kamat
May 13, 2024
Details
VA BRAVO 2 Study: Blue Light Cystoscopy Improves Outcomes in NMIBC Patients in Equal Access Setting - Stephen B Williams
May 7, 2024
Details
SunRISe-3 Trial: TAR-200 with or without Cetrelimab vs. BCG for BCG-Naive High-Risk NMIBC - Sam Chang
May 6, 2024
Details
Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer AUA/SUO Guideline - 2024 Amendment - Jeffrey Holzbeierlein
April 29, 2024
Details
Patient-Driven Outcomes in the CISTO Trial for High-Grade Non-Muscle Invasive Bladder Cancer - Angela Smith & John Gore
April 18, 2024
Details
Implementing Nadofaragene Firadenovec Treatment in NMIBC - Mark Tyson, Aimee Boden, & Meghann Davis
April 1, 2024
Details
Sequential Gemcitabine and Docetaxel Shows Promise for Intermediate-Risk NMIBC - Vignesh Packiam
March 14, 2024
Details
Intravesical Gemcitabine-Docetaxel Shows Durable Response in Recurrent High-Risk NMIBC After BCG - Mark Preston
March 13, 2024
Details
Age Alone Should Not Preclude BCG Therapy in NMIBC - Ashish Kamat
March 13, 2024
Details
Cretostimogene Grenadenorepvec in BCG-Unresponsive NMIBC: A Discussion on the BOND-003 and CORE1 Trials - Trinity Bivalacqua
March 12, 2024
Details
Understanding BCG Unresponsive NMIBC: Patient Perspectives, Treatment Options, and Clinical Guidance - Gautam Jayram
March 12, 2024
Details
Understanding Risk Stratification in Non-Muscle Invasive Bladder Cancer: Applying AUA Guidelines in Clinical Practice - Neal Shore
March 11, 2024
Details
Impact of Agent Orange Exposure on Non-Muscle Invasive Bladder Cancer Outcomes - Kyle Richards
March 7, 2024
Details
Combining Pembrolizumab and BCG Immunotherapies: The KEYNOTE-676 Trial in High-Risk NMIBC - Neal Shore
March 5, 2024
Details
Treatment Options Expand for BCG Unresponsive Bladder Cancer - Mark Tyson
February 22, 2024
Details
Nadofaragene Firadenovec: Adding to the Treatment Regimen Protocol - Joshua Meeks
February 21, 2024
Details
Predicting Recurrence and Monitoring Response in BCG-Unresponsive NMIBC with Urinary Minimal Residual Disease Detection - Vikram Narayan
February 20, 2024
Details
PIVOT-006 - A Study of Intravesical Cretostimogene Grenadenorepvec for Treatment of Patients with Intermediate-Risk, Non-Muscle Invasive Bladder Cancer - Mark Tyson
February 13, 2024
Details
Establishing Nadofaragene Firadenovec in a Large Urology Practice - Daniel Canter
February 12, 2024
Details
Real-World Use of Nadofaragene Firadenovec - Siamak Daneshmand
February 7, 2024
Details
Intravesical Nadofaragene Firadenovec Gene Therapy for BCG-Unresponsive NMIBC - Stephen Boorjian
January 22, 2024
Details
Bladder Cancer: En Bloc Resection Technique Shows Promise - David D'Andrea
January 12, 2024
Details
Chinese Trial Shows Blue Light Cystoscopy Superior for Bladder Cancer Detection - Hongxian Zhang
January 10, 2024
Details
BOND-003 Phase 3 Results: Revolutionizing Bladder Cancer Treatment with Intravesical Cretostimogene Grenadenorepvec Monotherapy for High-Risk BCG-Unresponsive NMIBC - Mark Tyson
January 8, 2024
Details
Exploring Promising Therapies and Genomic Insights in Bladder Cancer Research - Laura Bukavina
January 8, 2024
Details
Enhancing Bladder Cancer Diagnosis and Management with Advanced Visualization Techniques - Stephen B. Williams
January 4, 2024
Details
Consensus Recommendations to Optimize Low and Intermediate-Risk Bladder Cancer Studies, Journal Club - Rashid Sayyid & Zachary Klaassen
January 3, 2024
Details
Leaders Establish Consensus Criteria for High-Risk Bladder Cancer Trials, Journal Club - Rashid Sayyid & Zachary Klaassen
December 21, 2023
Details
Advances Bring Immunotherapy and Targeted Therapy Options for Non-Muscle Invasive Bladder Cancer - Kriti Mittal & Guru Sonpavde
December 19, 2023
Details
Exploring Bladder Cancer Innovations: A Deep Dive into ESMO 2023 - Morgan Rouprêt
December 13, 2023
Details
Operationalizing Blue Light in Your Practice - Gautam Jayram
December 12, 2023
Details
Cretostimogene Grenadenorepvec Therapy Aims to Fill an Unmet Need in the Bladder Cancer Armamentarium - Robert Svatek
December 12, 2023
Details
Novel Gene Therapy Shows Efficacy and Tolerable Safety Profile for Patients with Treatment-Resistant Bladder Cancer - Trinity Bivalacqua
November 28, 2023
Details
The Promise, Potential, and Practicality of Cxbladder in Modern Urologic Oncology - Mark Tyson, II
November 6, 2023
Details
A New Approach to Bladder Cancer: The ATLAS Trial's Exploration of UGN-102 and TURBT, Journal Club - Rashid Sayyid & Zachary Klaassen
August 25, 2023
Details
Blue Light Cystoscopy Delays Time To Recurrence in NMIBC Patients Treated in a Real-World Setting - Sia Daneshmand
August 3, 2023
Details
Exploring Erdafitinib: A Breakthrough in Non-Muscle Invasive Bladder Cancer Treatment - Siamak Daneshmand
June 12, 2023
Details
Gene Therapy for NMIBC: A New Era of Treatment - Colin Dinney
June 9, 2023
Details
Improving Bladder Cancer Treatment: An Insight into Vanderbilt's Innovative BCG Clinic - Meredith Donahue & Tara Cumming
June 8, 2023
Details
Pembrolizumab's Impact on Cystectomy-Free Survival in BCG Unresponsive Bladder Cancer from the KEYNOTE-057 Trial - Girish Kulkarni
May 19, 2023
Details
Managing Intermediate Risk Bladder Cancer: Treatment Strategies and Surveillance - Paolo Gontero & Gary Steinberg
May 19, 2023
Details
Promising Developments in the Theralase® Project of Intravesical Photodynamic Therapy for BCG Unresponsive Bladder Cancer - Girish Kulkarni
May 18, 2023
Details
TAR-200 in Combination with Cetrelimab for BCG Unresponsive Bladder Cancer (SunRISe-1) - Siamak Daneshmand
May 12, 2023
Details
Optimizing BCG Therapy in Bladder Cancer: Expert Insights on Managing Toxicity and Maximizing Efficacy - Badrinath Konety & Wassim Kassouf
May 12, 2023
Details
Debating Treatment Options for Very High-Risk Non-Muscle-Invasive Bladder Cancer: BCG vs. Radical Cystectomy - Morgan Rouprêt & Laura Mertens
May 12, 2023
Details
Gene Therapy and Pembrolizumab in BCG-Unresponsive CIS-Containing Population: Updated Results, Efficacy, and Correlative Studies - Roger Li
May 11, 2023
Details
En Bloc Resection vs. Standard Resection for Bladder Tumors: Multicenter Trial Results and Clinical Considerations - Jeremy Teoh
May 11, 2023
Details
Long-Term Survival Outcomes in Patients with BCG Unresponsive Non-Muscle Invasive Bladder Cancer: Evaluating Bladder-Sparing Treatment - Wei Shen Tan
May 11, 2023
Details
Gene Therapy for Non-muscle Invasive Bladder Cancer - Roger Li
May 8, 2023
Details
Assessing the Effectiveness of N-803 for BCG Unresponsive Bladder Cancer: Promising Complete Remission Rates and Improved Long-Term Response - Patrick Soon-Shiong
May 5, 2023
Details
Gemcitabine and Docetaxel Therapy Associated with Better Outcomes than BCG Therapy for High-Risk Non-Muscle-Invasive Bladder Cancer: A Retrospective Cohort Study - Vignesh Packiam
April 20, 2023
Details
The Importance of Proper Transurethral Resection of Bladder Tumors (TURBT) in Bladder Cancer Treatment - Arnulf Stenzl
April 10, 2023
Details
Updated Consensus Definition and Management Recommendations from the International Bladder Cancer Group: Intermediate-risk Non-muscle-invasive Bladder Cancer - Wei Shen Tan
March 14, 2023
Details
HIVEC-II Phase 2 Trial Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk NMIBC - Wei Shen Tan
March 14, 2023
Details
Results from Cohort B of the Phase 2 KEYNOTE-057 Trial, Pembrolizumab Monotherapy for Patients with High-Risk Non–muscle-Invasive Bladder Cancer Unresponsive to BCG - Andrea Necchi
March 16, 2023
Details
Clinical Perspective on Recurrence Mechanisms of Non-muscle Invasive Bladder Cancer – Jeremy Teoh
March 6, 2023
Details
The Clinical Benefits of Blue Light Cystoscopy in the Ambulatory Surgical Centers - Neal Shore
March 5, 2023
Details
Cell-Free Urinary DNA Predictive Impact on Patients with Non-Muscle Invasive Bladder Cancer - Kyle Rose
February 22, 2023
Details
The Explosion of Intravesical Therapy for Non-Muscle Invasive Bladder Cancer LUGPA 2022 Presentation - Colin Dinney
December 16, 2022
Details
Blue Light Powered by Saphira® for the Detection of Non Muscle-Invasive Bladder Cancer - Max Kates & Trinity J. Bivalacqua
November 16, 2022
Details
QUILT Trial: A Comprehensive Look at BCG Unresponsive Bladder Cancer and the Role of N-803 - Karim Chamie
November 15, 2022
Details
Non Muscle-Invasive Bladder Cancer: An Overview of Potential New Treatment Options - Beyond the Abstract
November 7, 2022
Details
Underlying Mechanism of Action of N-803 + BCG Inducing Durable Complete Response in BCG Unresponsive NMIBC -Patrick Soon-Shiong
October 27, 2022
Details
Pembrolizumab Monotherapy for the Treatment of High-Risk Non-Muscle-Invasive Bladder Cancer Unresponsive to BCG the KEYNOTE-057 Study, Journal Club – Christopher Wallis & Zachary Klaassen
September 27, 2022
Details
Advances in Treatment Options for BCG Unresponsive CIS and Papillary Non-Muscle Invasive Bladder Cancer - QUILT 3.032 - Sam Chang
July 19, 2022
Details
BCG Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer - Seth Lerner
June 14, 2022
Details
Demonstrated Underuse of Blue Light Cystoscopy for Bladder Cancer in the United States - Patrick Lewicki
January 11, 2022
Details
The Association of Smoking Status with Recurrence in Patients with Predominantly High-Risk Recurrent NMIBC - Richard Matulewicz
October 1, 2021
Details
The Natural History of High-Risk NMIBC: Novel Therapies vs Cystectomy - Angela Smith
July 1, 2021
Details
The Role of Radiology and Radiomics in Staging & Risk Stratification of NMIBC - Manjiri Dighe
July 1, 2021
Details
Novel Immune Checkpoint Axis To Understand BCG Resistance and Improve Treatment in Non-muscle Invasive Bladder Cancer - Amir Horowitz & John Sfakianos
May 10, 2021
Details
Conundrums in Bacillus Calmette Guerin (BCG) Unresponsive Nonmuscle Invasive Bladder Cancer Trials - Roger Li
May 8, 2021
Details
Combining BCG and Intravesical Gemcitabine (GBIG) for Patients with BCG-Relapsing High-Grade NMIBC Cancer A Phase 1/2 Trial- Eugene Pietzak
May 5, 2021
Details
The Use of Blue Light Cystoscopy for Both Hospital and Outpatient Clinic - Yair Lotan and Daniel Parker
May 5, 2021
Details
Improved Tumor Visibility, Detection Rate and Reduced Recurrence Rates After TURBT - Siamak Daneshmand and Marek Babjuk
April 21, 2021
Details
Molecular Landscape of NMIBC and Risk Factors for Progression A Lecture & Discussion - Eugene Pietzak
April 12, 2021
Details
Trained Immunity as a Molecular Mechanism for BCG Immunotherapy - Sita Vermeulen
January 27, 2021
Details
Nadofaragene Firadenovec for BCG Unresponsive NMIBC - Girish Kulkarni
January 5, 2021
Details
How to Define Treatment Failure After BCG Treatment for Nonmuscle-Invasive Bladder Cancer - Peter Black
October 14, 2020
Details
High-Risk Non Muscle-Invasive BCG Unresponsive Bladder Cancer - Molecular Subtypes - Woonyoung Choi
October 14, 2020
Details
Adherence to Guidelines-Based Management of Non-Muscle Invasive Bladder Cancer Among Society of Urologic Oncology (SUO) Members - Justin T. Matulay
August 4, 2020
Details
Results of the SUO CTC Phase III Nadofaragene Firadenovec Trial for BCG Unresponsive NMIBC - Colin Dinney
July 6, 2020
Details
Phase III Nadofaragene Firadenovec for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer - Joshua J. Meeks
February 28, 2020
Details
Pembrolizumab in the BCG-unresponsive NMIBC Patients - Arjun Balar
February 22, 2020
Details